Pyrimidine Derivatives Targeting TLR7 for Immunomodulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral or allergic diseases and cancers lack effective immunomodulating agents that specifically target TLR7 receptors.
Innovation Solution
Development of pyrimidine derivatives with specific structures that act as immunomodulators by targeting TLR7 receptors, thereby modulating immune responses for therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pyrimidine derivatives are developed to target TLR7 receptors for immunomodulation, then therapeutic effectiveness for viral infections, allergic diseases, and cancers is improved, but the complexity of drug development and characterization increases
Solution Approach 1:
The patent segments the immunomodulatory function into specific pyrimidine derivative compounds that selectively target TLR7 receptors. By dividing the broad immunomodulation goal into specific molecular entities with defined structures (Formula 1 and Formula 2), the patent enables focused development and characterization of individual compounds rather than attempting to develop a single complex multi-target agent.
Solution Approach 2:
The patent applies parameter changes by systematically varying structural parameters of pyrimidine derivatives (substituents at positions R1a, R1b, R2, R3, R4, R5, R6 and linkers L1, L2) to optimize TLR7 binding affinity and immunomodulatory activity. This allows tuning of drug properties to achieve desired therapeutic effectiveness while managing development complexity through structured optimization.
2Reliability
If specific structural features are incorporated into pyrimidine derivatives to enhance TLR7 targeting, then immunomodulating activity is improved, but the difficulty of synthesis and manufacturing increases
Solution Approach 1:
The patent segments the molecular structure into distinct functional modules: the pyrimidine core, substituent groups (R1a-R6), and linker moieties (L1, L2). This segmentation allows each component to be synthesized separately using standard organic chemistry techniques, then assembled through coupling reactions, thereby managing synthesis complexity while maintaining TLR7 targeting specificity.
Solution Approach 2:
The patent employs universal building blocks and common synthetic intermediates that can be used across multiple compound variants. The pyrimidine core and various substituent groups can be prepared using standardized protocols, and the linker structures are designed to facilitate conventional coupling reactions, enabling efficient manufacturing of multiple TLR7-targeting agents from a common platform.
Data Source
AI summary
The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via TLR7 which are useful in the treatment of viral infections and cancers.